Search

Your search keyword '"Hagemeister, Fredrick B."' showing total 322 results
Start Over Author "Hagemeister, Fredrick B." Search Limiters Available in Library Collection
322 results on '"Hagemeister, Fredrick B."'

1. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

Author

Gurumurthi, Ashwath, Chin, Collin K., Feng, Lei, Fowler, Nathan H., Strati, Paolo, Hagemeister, Fredrick B., Fayad, Luis E., Westin, Jason R., Obi, Chizobam, Arafat, Janine, Nair, Ranjit, Steiner, Raphael E., Neelapu, Sattva S., Flowers, Christopher R., and Nastoupil, Loretta J.

Published
2024
Full Text
View/download PDF

3. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Author

Janku, Filip, Park, Haeseong, Call, S Greg, Madwani, Kiran, Oki, Yasuhiro, Subbiah, Vivek, Hong, David S, Naing, Aung, Velez-Bravo, Vivianne M, Barnes, Tamara G, Hagemeister, Fredrick B, Falchook, Gerald S, Karp, Daniel D, Wheler, Jennifer J, Piha-Paul, Sarina A, Garrido-Laguna, Ignacio, Shpall, Elizabeth J, Fayad, Luis E, Neelapu, Sattva S, Meric-Bernstam, Funda, Kurzrock, Razelle, and Fanale, Michelle A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Rare Diseases, Transplantation, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Everolimus, Female, Hematopoietic Stem Cell Transplantation, Histone Deacetylase Inhibitors, Histone Deacetylases, Hodgkin Disease, Humans, Male, Middle Aged, Recurrence, Sirolimus, Stem Cell Transplantation, TOR Serine-Threonine Kinases, Vorinostat, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePreclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma.Patients and methodsDuring the dose-escalation study (ClinicalTrials.gov number: NCT01087554) with the HDAC inhibitor vorinostat and the mTOR inhibitor sirolimus (V+S), a patient with Hodgkin lymphoma refractory to nine prior therapies demonstrated a partial response (PR) lasting for 18.5 months, which promoted additional enrollment of patients with Hodgkin lymphoma as well as exploration of an alternative combination of vorinostat and mTOR inhibitor everolimus (V+E).ResultsA total of 40 patients with refractory Hodgkin lymphoma received V+S (n = 22) or V+E (n = 18). Patients received a median of five prior therapies, including brentuximab (n = 39), autologous stem cell transplantation (n = 26), and allogeneic stem cell transplantation (n = 12). The most frequent grade ≥3 treatment-related adverse event was thrombocytopenia in 55% and 67% of patients treated with V+S and V+E, respectively. Complete response was reported in 6 (27%) patients treated with V+S and 2 (11%) patients treated with V+E, and PR was reported in 6 patients (27%) treated with V+S and 4 (22%) patients treated with V+E (objective response rate of 55% and 33%, respectively). In summary, combined HDAC and mTOR inhibition had encouraging activity in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma and warrants further investigation.ConclusionsCombined HDAC and mTOR inhibition has salutary activity in patients with relapsed refractory Hodgkin lymphoma and warrants further investigation.

Published
2020

4. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Author

Xu-Monette, Zijun Y, Zhang, Hongwei, Zhu, Feng, Tzankov, Alexandar, Bhagat, Govind, Visco, Carlo, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés JM, Møller, Michael B, Parsons, Benjamin M, van Krieken, J Han, Piris, Miguel A, Winter, Jane N, Hagemeister, Fredrick B, Shahbaba, Babak, De Dios, Ivan, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher, and Young, Ken H

Subjects
Orphan Drug, Human Genome, Hematology, Cancer, Rare Diseases, Lymphoma, Biotechnology, Genetics, Generic health relevance, Good Health and Well Being, Artificial Intelligence, B-Lymphocytes, Germinal Center, High-Throughput Nucleotide Sequencing, Humans, Lymphoma, Large B-Cell, Diffuse
Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights. Genetic subtypes uncovered recently are based on distinct genetic alterations in DLBCL, which are different from the COO subtypes defined by gene expression signatures of normal B cells retained in DLBCL. We hypothesize that classifiers incorporating both genome-wide gene-expression and pathogenetic variables can improve the therapeutic significance of DLBCL classification. To develop such refined classifiers, we performed targeted RNA sequencing (RNA-Seq) with a commercially available next-generation sequencing (NGS) platform in a large cohort of 418 DLBCLs. Genetic and transcriptional data obtained by RNA-Seq in a single run were explored by state-of-the-art artificial intelligence (AI) to develop a NGS-COO classifier for COO assignment and NGS survival models for clinical outcome prediction. The NGS-COO model built through applying AI in the training set was robust, showing high concordance with COO classification by either Affymetrix GeneChip microarray or the NanoString Lymph2Cx assay in 2 validation sets. Although the NGS-COO model was not trained for clinical outcome, the activated B-cell-like compared with the germinal-center B-cell-like subtype had significantly poorer survival. The NGS survival models stratified 30% high-risk patients in the validation set with poor survival as in the training set. These results demonstrate that targeted RNA-Seq coupled with AI deep learning techniques provides reproducible, efficient, and affordable assays for clinical application. The clinical grade assays and NGS models integrating both genetic and transcriptional factors developed in this study may eventually support precision medicine in DLBCL.

Published
2020

5. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Published
2022
Full Text
View/download PDF

7. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Author

Albitar, Maher, Zhang, Hong, Goy, Andre, Xu-Monette, Zijun Y., Bhagat, Govind, Visco, Carlo, Tzankov, Alexandar, Fang, Xiaosheng, Zhu, Feng, Dybkaer, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Hagemeister, Fredrick B., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Parsons, Benjamin M., van Krieken, J. Han, Piris, Miguel A., Winter, Jane N., Li, Yong, Xu, Bing, and Young, Ken H.

Published
2022
Full Text
View/download PDF

8. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

9. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Author

Takahashi, Koichi, Sivina, Mariela, Hoellenriegel, Julia, Oki, Yasuhiro, Hagemeister, Fredrick B, Fayad, Luis, Romaguera, Jorge E, Fowler, Nathan, Fanale, Michelle A, Kwak, Larry W, Samaniego, Felipe, Neelapu, Sattva, Xiao, Lianchun, Huang, Xuelin, Kantarjian, Hagop, Keating, Michael J, Wierda, William, Fu, Kai, Chan, Wing C, Vose, Julie M, O'Brien, Susan, Davis, Richard E, and Burger, Jan A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Rare Diseases, Lymphoma, Hematology, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Adenine, Antineoplastic Agents, B-Cell Activation Factor Receptor, Biomarkers, Tumor, Cell Line, Tumor, Chemokine CCL3, Chemokine CCL4, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Humans, Lymphoma, Large B-Cell, Diffuse, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Signal Transduction, chemokines, diffuse large B-cell lymphoma, lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

B cell receptor (BCR) signalling is an important pathway in diffuse large B cell lymphoma (DLBCL). In response to BCR triggering, normal and malignant B cells secrete the chemokines CCL3 and CCL4 to attract accessory cells to the tissue microenvironment. We measured CCL3 and CCL4 serum concentrations in 102 patients with newly diagnosed DLBCL by enzyme-linked immunosorbent assay, investigated their prognostic impact and validated our findings in an independent cohort of 51 patient samples. We also tested CCL3 and CCL4 secretion by DLBCL cells, and the influence of BTK inhibitors on the secretion of these chemokines. High CCL3 (≥40 pg/ml) serum concentrations correlated with higher international prognostic index, lactate dehydrogenase and β2 microglobulin, as did CCL4 (≥180 pg/ml) with advanced Ann Arbor stages. High CCL3 levels correlated with significantly shorter progression-free and overall survival. The in vitro studies demonstrated that activated B cell-like, but not germinal centre B cell-like DLBCL cells, secrete high levels of CCL3 and CCL4 after BCR triggering, which was exquisitely sensitive to BCR pathway inhibition. These findings support CCL3 and CCL4 protein concentrations as biomarkers for BCR pathway activation and prognosis in DLBCL.

Published
2015

10. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential

Author

Li, Yong, primary, Xu-Monette, Zijun Y., additional, Abramson, Jeremy, additional, Sohani, Aliyah R., additional, Bhagat, Govind, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Zhang, Shanxiang, additional, Dybkaer, Karen, additional, Pan, Zenggang, additional, Xu, Min, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Go, Heounjeong, additional, van Krieken, J. Han, additional, Winter, Jane N., additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Møller, Michael B., additional, Piris, Miguel A., additional, Wang, Yingjun, additional, Zhang, Mingzhi, additional, and Young, Ken H., additional

Published
2023
Full Text
View/download PDF

12. Additional file 1 of PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Abstract

Additional file 1: Methods; Figure S1. Representative pictures showing different cell densities of CD30+PD-L1+ cells. A-C) Multiplex immunofluorescence image of a case with low cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells median: 20.46 cells/mm2, respectively. D-E) Multiplex immunofluorescence image of a case with high cell density of CD30+, PD-L1+, and CD30+PD-L1+ cells (median: 604.62 cells/mm2), respectively. Supplementary Table 1.

Published
2023
Full Text
View/download PDF

13. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL

Author

Nair, Ranjit, primary, Ayers, Amy, additional, Nastoupil, Loretta J., additional, Gunther, Jillian R., additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Miranda, Roberto N., additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Steiner, Raphael, additional, Strati, Paolo, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Chihara, Dai, additional, Wang, Michael L., additional, Malpica Castillo, Luis E, additional, Saini, Neeraj, additional, Jain, Preetesh, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Green, Michael R, additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Marques-Piubelli, Mario L., additional, Vega, Francisco, additional, Noorani, Mansoor, additional, Ahmed, Sairah, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, Feng, Lei, additional, and Iyer, Swaminathan Padmanabhan, additional

Published
2022
Full Text
View/download PDF

14. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Author

Li, Xubin, primary, Deng, Qing, additional, Henderson, Jared, additional, Watson, Grace, additional, Deaton, Laurel, additional, Cain, Taylor, additional, Fayad, Luis, additional, Iyer, Swaminathan Padmanabhan, additional, Hagemeister, Fredrick B., additional, Nastoupil, Loretta J., additional, Fowler, Nathan H., additional, Westin, Jason, additional, Steiner, Raphael, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, and Green, Michael R, additional

Published
2022
Full Text
View/download PDF

15. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

Author

Han, Guangchun, primary, Deng, Qing, additional, Marques-Piubelli, Mario L., additional, Dai, Enyu, additional, Dang, Minghao, additional, Ma, Man Chun John, additional, Li, Xubin, additional, Yang, Haopeng, additional, Henderson, Jared, additional, Kudryashova, Olga, additional, Meerson, Mark, additional, Isaev, Sergey, additional, Kotlov, Nikita, additional, Nomie, Krystle J., additional, Bagaev, Alexander, additional, Parra, Edwin R., additional, Solis Soto, Luisa M., additional, Parmar, Simrit, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Iyer, Swaminathan P., additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Strati, Paolo, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Vega, Francisco, additional, Wang, Linghua, additional, and Green, Michael R., additional

Published
2022
Full Text
View/download PDF

16. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma.

Author

Steiner, Raphael E., Parra, Edwin R., Vega, Francisco, Feng, Lei, Westin, Jason R., Neelapu, Sattva S., Strati, Paolo, Green, Michael R., Flowers, Christopher R., Solis, Luisa M., Wistuba, Ignacio I., Ahmed, Sairah, Nair, Ranjit, Hagemeister, Fredrick B., Noorani, Mansoor, and Marques-Piubelli, Mario L.

Subjects
MACROPHAGES, PROGNOSIS, THYMUS tumors, NON-Hodgkin's lymphoma, LYMPHOMAS, DISEASE relapse
Abstract

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1+ macrophages is associated with favorable features, such as early disease stage and the absence of B-symptoms, and indicate that a high percentage of PD-L1+ macrophages and high densities of CD30+PD-L1+ cells and CD30+ cells might be associated with a lower risk of relapse within 12 months of therapy initiation. Further studies are needed to develop a biomarker signature predictive of treatment response with therapeutic consequences for patients with newly diagnosed PMBCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma

Author

Xu-Monette, Zijun Y., primary, Wei, Li, additional, Fang, Xiaosheng, additional, Au, Qingyan, additional, Nunns, Harry, additional, Nagy, Máté, additional, Tzankov, Alexandar, additional, Zhu, Feng, additional, Visco, Carlo, additional, Bhagat, Govind, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Sun, Xiaoping, additional, Han, Xin, additional, Go, Heounjeong, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Parsons, Benjamin M., additional, van Krieken, J. Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Li, Yong, additional, Xu, Bing, additional, Albitar, Maher, additional, You, Hua, additional, and Young, Ken H., additional

Published
2022
Full Text
View/download PDF

20. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

Author

Westin, Jason R., primary, Steiner, Raphael, additional, Feng, Lei, additional, Strati, Paolo, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta, additional, Chihara, Dai, additional, Hagemeister, Fredrick B., additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, Davis, Eric, additional, and Green, Michael R, additional

Published
2021
Full Text
View/download PDF

21. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma

Author

Chihara, Dai, primary, Nastoupil, Loretta, additional, Strati, Paolo, additional, Samaniego, Felipe, additional, Feng, Lei, additional, Rodriguez, Maria Alma, additional, Fayad, Luis, additional, Westin, Jason R., additional, Hagemeister, Fredrick B., additional, Wang, Michael, additional, Neelapu, Sattva S., additional, and Fowler, Nathan H., additional

Published
2021
Full Text
View/download PDF

22. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series

Author

Nair, Ranjit, primary, Deen, Nafis, additional, Ahmed, Sairah, additional, Miranda, Roberto N., additional, Fowler, Nathan H., additional, Fayad, Luis, additional, Steiner, Raphael E, additional, Hagemeister, Fredrick B., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Strati, Paolo, additional, Malpica-Castillo, Luis, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Gunther, Jillian R., additional, Flowers, Christopher R., additional, Medeiros, L. Jeffrey, additional, Nieto, Yago, additional, Ramdial, Jeremy L., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta, additional, Green, Michael R, additional, Wang, Michael, additional, Vega, Francisco, additional, Feng, Lei, additional, Iyer, Swaminathan Padmanabhan, additional, and Westin, Jason R., additional

Published
2021
Full Text
View/download PDF

23. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma

Author

Pinnix, Chelsea C., primary, Dabaja, Bouthaina S., additional, Gunther, Jillian R., additional, Fang, Penny, additional, Wu, Susan, additional, Nastoupil, Loretta, additional, Strati, Paolo, additional, Nair, Ranjit, additional, Ahmed, Sairah, additional, Steiner, Raphael E, additional, Malpica-Castillo, Luis, additional, Chihara, Dai, additional, Jain, Preetesh, additional, Fayad, Luis, additional, Westin, Jason R., additional, Neelapu, Sattva S., additional, Rodriguez, Maria Alma, additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Wang, Michael, additional, Samaniego, Felipe, additional, Fowler, Nathan H., additional, Flowers, Christopher R., additional, Feng, Lei, additional, Chi, Linda, additional, and Esmaeli, Bita, additional

Published
2021
Full Text
View/download PDF

24. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma

Author

Steiner, Raphael E, primary, Strati, Paolo, additional, Flowers, Christopher R., additional, Neelapu, Sattva S., additional, Green, Michael R, additional, Nastoupil, Loretta, additional, Hagemeister, Fredrick B., additional, Feng, Lei, additional, Ahmed, Sairah, additional, Nair, Ranjit, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Rodriguez, Maria Alma, additional, and Westin, Jason R., additional

Published
2021
Full Text
View/download PDF

25. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Author

Cherng, Hua-Jay J., primary, Sun, Ryan, additional, Yang, Haopeng, additional, Deng, Qing, additional, Fayad, Luis, additional, Fowler, Nathan H., additional, Parmar, Simrit, additional, Ahmed, Sairah, additional, Steiner, Raphael E, additional, Hagemeister, Fredrick B., additional, Lee, Hun Ju, additional, Nair, Ranjit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Iyer, Swaminathan P, additional, Nastoupil, Loretta, additional, Neelapu, Sattva S., additional, Strati, Paolo, additional, Westin, Jason R., additional, and Green, Michael R, additional

Published
2021
Full Text
View/download PDF

26. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Author

You, Hua, primary, Xu-Monette, Zijun Y., additional, Wei, Li, additional, Nunns, Harry, additional, Nagy, Máté L., additional, Bhagat, Govind, additional, Fang, Xiaosheng, additional, Zhu, Feng, additional, Visco, Carlo, additional, Tzankov, Alexandar, additional, Dybkaer, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Hsi, Eric D., additional, Hagemeister, Fredrick B., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J.M., additional, Møller, Michael B., additional, Parsons, Benjamin M., additional, Van Krieken, J. Han, additional, Piris, Miguel A., additional, Winter, Jane N., additional, Li, Yong, additional, Au, Qingyan, additional, Xu, Bing, additional, Albitar, Maher, additional, and Young, Ken H., additional

Published
2021
Full Text
View/download PDF

27. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Author

Westin, Jason R., primary, Nastoupil, Loretta J., additional, Fayad, Luis, additional, Hagemeister, Fredrick B., additional, Oki, Yasuhiro, additional, Turturro, Francesco, additional, Ahmed, Sairah, additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Steiner, Raphael Eric, additional, Nair, Ranjit, additional, Parmar, Simrit, additional, Young, Ken H., additional, McDonnell, Timothy J., additional, Chuang, Hubert, additional, Green, Michael R, additional, Neelapu, Sattva S, additional, and Davis, Eric, additional

Published
2019
Full Text
View/download PDF

28. Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Author

Pinnix, Chelsea C, primary, Gunther, Jillian R, additional, Dabaja, Bouthaina S., additional, Adkins, Sherry, additional, Hawkins, Misha, additional, Westin, Jason R., additional, Fayad, Luis, additional, Ahmed, Sairah, additional, Fowler, Nathan H., additional, Hagemeister, Fredrick B., additional, Iyer, Swaminathan P., additional, Rodriguez, Maria Alma, additional, Lee, Hun Ju, additional, Steiner, Raphael E, additional, Nair, Ranjit, additional, Strati, Paolo, additional, Parmar, Simrit, additional, Samaniego, Felipe, additional, Wang, Michael, additional, Neelapu, Sattva S, additional, and Nastoupil, Loretta J., additional

Published
2019
Full Text
View/download PDF

29. Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Author

Nastoupil, Loretta J., primary, Neelapu, Sattva S, additional, Davis, Eric, additional, Samaniego, Felipe, additional, Fowler, Nathan H, additional, Westin, Jason R., additional, Lee, Hun Ju, additional, Wang, Michael, additional, Hagemeister, Fredrick B., additional, Beer, Philip, additional, Cecil, Alexander R. L., additional, Dow, James, additional, McHale, Duncan, additional, Silva, Franck, additional, Ward, Penny, additional, Yavari, Arash, additional, and Shuttleworth, Stephen Joseph, additional

Published
2019
Full Text
View/download PDF

30. A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Author

Westin, Jason R., primary, Fowler, Nathan H., additional, Nastoupil, Loretta J., additional, Neelapu, Sattva S, additional, Lee, Hun Ju, additional, Hagemeister, Fredrick B., additional, Rodriguez, Maria Alma, additional, Steiner, Raphael E, additional, Ahmed, Sairah, additional, Parmar, Simrit, additional, Nair, Ranjit, additional, Harrison, Rebecca, additional, and Fayad, Luis, additional

Published
2019
Full Text
View/download PDF

31. A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Author

Fowler, Nathan H, primary, Nastoupil, Loretta J., primary, Chin, Collin, primary, Strati, Paolo, primary, Hagemeister, Fredrick B., primary, Fayad, Luis E., primary, Westin, Jason R., primary, Forbes, Sheryl G, primary, Arafat, Janine, primary, Feng, Lei, primary, Nair, Ranjit, primary, Steiner, Raphael E, primary, Samaniego, Felipe, primary, and Neelapu, Sattva S, primary

Published
2019
Full Text
View/download PDF

32. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Author

Nastoupil, Loretta J., primary, Westin, Jason R., primary, Hagemeister, Fredrick B., primary, Lee, Hun Ju, primary, Fayad, Luis, primary, Samaniego, Felipe, primary, Ahmed, Sairah, primary, Claret, Linda, primary, Steiner, Raphael E, primary, Nair, Ranjit, primary, Parmar, Simrit, primary, Rodriguez, Maria Alma, primary, Wang, Michael L., primary, Green, Michael R, primary, Davis, Eric, primary, Neelapu, Sattva S, primary, and Fowler, Nathan H, primary

Published
2019
Full Text
View/download PDF

33. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Author

Strati, Paolo, primary, Ahmed, Mohamed Amin, additional, Fowler, Nathan H., additional, Nastoupil, Loretta J., additional, Samaniego, Felipe, additional, Fayad, Luis E., additional, Hagemeister, Fredrick B., additional, Romaguera, Jorge E., additional, Rodriguez, Alma, additional, Wang, Michael, additional, Westin, Jason R., additional, Cheah, Chan, additional, Noorani, Mansoor, additional, Feng, Lei, additional, Davis, Richard E., additional, and Neelapu, Sattva S., additional

Published
2019
Full Text
View/download PDF

35. SIRPα+macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

Author

Marques-Piubelli, Mario L., Parra, Edwin R., Feng, Lei, Soto, Luisa Solis, Gallardo, Mariana, Gouni, Sushanth, Samaniego, Felipe, Noorani, Mansoor, Hagemeister, Fredrick B., Westin, Jason R., Lee, Hun Ju, Rodriguez, Maria A., Neelapu, Sattva S., Gunther, Jillian R., Fowler, Nathan H., Flowers, Christopher R., Wistuba, Ignacio I., Nastoupil, Loretta J., Vega, Francisco, and Strati, Paolo

Abstract

Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R2). Moreover, mechanisms of resistance to R2in FL remain unclear, with increased protumoral macrophages suspected as a major contributory culprit to this phenomenon. This retrospective study analyzed the outcome of patients with advanced-stage FL grade 1 to 3A who relapsed or progressed after frontline R2. A multiplex immunofluorescence macrophage panel, including CD47, CD14, CD68, CD115 (also known as colony-stimulating factor 1 receptor [CSF1R]), CD163, CD172a (also known as signal regulatory protein α [SIRPα]), and CD274 (also known as programmed cell death-ligand 1 [PDL1]), was used to stain tissue biopsy specimens collected before initiation of R2and at the time of progression. Among 156 patients with advanced-stage FL treated with frontline R2, 33 (21%) relapsed or progressed and required second-line therapy, after a median of 33 months (range, 1-122 months). Second-line therapy was chemoimmunotherapy in 16 (48%) patients and other therapy in 17 (52%). The overall response rate was 78%, and complete response rate was 72%. Median progression-free survival was significantly longer in patients who received chemoimmunotherapy compared with other therapy (99 vs 25 months; P= .004). Three macrophage populations were significantly increased in tissue samples collected at progression compared with before frontline treatment: CD68+CD115+(P= .02), CD68+CD115+CD172a+(P= .02), and CD68+CD163+CD172a+(P= .01). Chemoimmunotherapy is an effective treatment strategy for patients with FL who relapse after frontline R2. Therapies targeting specific macrophage populations may yield novel approaches for improving outcomes with frontline R2.

Published
2022
Full Text
View/download PDF

38. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Author

Strati, Paolo, primary, Nastoupil, Loretta J., additional, Davis, Richard E, additional, Fayad, Luis E., additional, Fowler, Nathan, additional, Hagemeister, Fredrick B., additional, Kwak, Larry, additional, Oki, Yasuhiro, additional, Wang, Michael, additional, Westin, Jason, additional, Ruben, Charnelle E., additional, Wesson, Emily T., additional, Piekarz, Richard, additional, Fanale, Michelle A., additional, and Lee, Hun Ju, additional

Published
2019
Full Text
View/download PDF

39. Frontline antibiotic therapy for early‐stage Helicobacter pylori ‐negative gastric MALT lymphoma

Author

Strati, Paolo, primary, Lee, Seung Tae, additional, Teegavarupu, Purnima, additional, Karri, Anusha, additional, Anireddy, Saswatha, additional, Hagemeister, Fredrick B., additional, Romaguera, Jorge, additional, Fayad, Luis E., additional, Rodriguez, Maria A., additional, Samaniego, Felipe, additional, Fowler, Nathan, additional, Westin, Jason, additional, Wang, Michael, additional, Lee, Hun Ju, additional, Pinnix, Chelsea, additional, Gunther, Jillian R., additional, Dabaja, Bouthaina, additional, Feng, Lei, additional, Davis, Richard Eric, additional, and Neelapu, Sattva S., additional

Published
2019
Full Text
View/download PDF

40. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.

Author

Hua You, Xu-Monette, Zijun Y., Li Wei, Nunns, Harry, Nagy, Máté L., Bhagat, Govind, Xiaosheng Fang, Feng Zhu, Visco, Carlo, Tzankov, Alexandar, Dybkaer, Karen, Chiu, April, Tam, Wayne, Youli Zu, Hsi, Eric D., Hagemeister, Fredrick B., Jooryung Huh, Ponzoni, Maurilio, Ferreri, Andrés J. M., and Møller, Michael B.

Subjects
DIFFUSE large B-cell lymphomas, SINGLE nucleotide polymorphisms, EPIGENETICS, IMMUNE checkpoint inhibitors, GENETIC mutation
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma with high mutation burdens but a low response rate to immune checkpoint inhibitors. In this study, we performed targeted next-generation sequencing and fluorescent multiplex immunohistochemistry, and investigated the clinical significance and immunological effect of mutation numbers in 424 DLBCL patients treated with standard immunochemotherapy. We found that KMT2D and TP53 nonsynonymous mutations (MUT) were significantly associated with increased nonsynonymous mutation numbers, and that high mutation numbers (MUThigh) were associated with significantly poorer clinical outcome in germinal center B-cell-like DLBCL with wild-type TP53. To understand the underlying mechanisms, we identified a gene-expression profiling signature and the association of MUThigh with decreased T cells in DLBCL patients with wild-type TP53. On the other hand, in overall cohort, MUThigh was associated with lower PD-1 expression in T cells and PD-L1 expression in macrophages, suggesting a positive role of MUThigh in immune responses. Analysis in a whole-exome sequencing dataset of 304 patients deposited by Chapuy et al. validated the correlation of MUT-KMT2D with genomic complexity and the significantly poorer survival associated with higher numbers of genomic single nucleotide variants in activated B-cell-like DLBCL with wild-type TP53. Together, these results suggest that KMT2D inactivation or epigenetic dysregulation has a role in driving DLBCL genomic instability, and that genomic complexity has adverse impact on clinical outcome in DLBCL patients with wild-type TP53 treated with standard immunochemotherapy. The oncoimmune data in this study have important implications for biomarker and therapeutic studies in DLBCL. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Author

Khouri, Issa F., Saliba, Rima M., Giralt, Sergio A., Lee, Ming-Sheng, Okoroji, Grace-Julia, Hagemeister, Fredrick B., Korbling, Martin, Younes, Anas, Ippoliti, Cindy, Gajewski, James L., McLaughlin, Peter, Anderlini, Paolo, Donato, Michele L., Cabanillas, Fernando F., and Champlin, Richard E.

Published
2001
Full Text
View/download PDF

42. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

Author

Chihara, Dai, primary, Fanale, Michelle A., additional, Miranda, Roberto N., additional, Noorani, Mansoor, additional, Westin, Jason R., additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Romaguera, Jorge E., additional, Samaniego, Felipe, additional, Turturro, Francesco, additional, Lee, Hun J., additional, Neelapu, Sattva S., additional, Rodriguez, M. Alma, additional, Wang, Michael, additional, Fowler, Nathan H., additional, Davis, Richard E., additional, Medeiros, L. Jeffrey, additional, and Oki, Yasuhiro, additional

Published
2018
Full Text
View/download PDF

43. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

Author

Lee, Hun Ju, primary, Romaguera, Jorge E., additional, Feng, Lei, additional, Desai, Aakash P., additional, Zhang, Liang, additional, Fanale, Michelle, additional, Samaniego, Felipe, additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Rodriguez, Maria A., additional, Medeiros, Jeffrey L., additional, Hartig, Kimberly, additional, Nomie, Krystle, additional, Ahmed, Makhdum, additional, Badillo, Maria, additional, Ye, Haige, additional, Oki, Yasuhiro, additional, Lin, Pei, additional, Nastoupil, Loretta, additional, Westin, Jason, additional, and Wang, Michael, additional

Published
2017
Full Text
View/download PDF

44. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Author

Hu, Bei, primary, Younes, Anas, additional, Claret, Linda, additional, Feng, Lei, additional, Westin, Jason R., additional, Fowler, Nathan, additional, Neelapu, Sattva, additional, Hagemeister, Fredrick B., additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Fayad, Luis E., additional, Nastoupil, Loretta J., additional, Copeland, Amanda R, additional, Fanale, Michelle A, additional, and Oki, Yasuhiro, additional

Published
2016
Full Text
View/download PDF

45. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience

Author

Sathyanarayanan, Vishwanath, primary, Oki, Yasuhiro, additional, Issa, Amir K, additional, Ahmed, Mohamed Amin, additional, Noorani, Mansoor, additional, Fanale, Michelle A, additional, Hagemeister, Fredrick B., additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, Fowler, Nathan, additional, Turturro, Francesco, additional, Davis, Eric Richard, additional, Rodriguez, Alma, additional, Wang, Michael, additional, Feng, Lei, additional, Young, Ken H., additional, McDonnell, Timothy J., additional, Pinnix, Chelsea C, additional, Fayad, Luis E., additional, and Westin, Jason R., additional

Published
2016
Full Text
View/download PDF

46. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

Author

Wang, Michael, primary, Lee, Hun Ju, additional, Thirumurthi, Selvi, additional, Chuang, Hubert H, additional, Hagemeister, Fredrick B., additional, Westin, Jason R., additional, Fayad, Luis E., additional, Samaniego, Felipe, additional, Turturro, Francesco, additional, Chen, Wendy, additional, Oriabure, Onyeka, additional, Huang, Steven Y, additional, Li, Shaoying, additional, Zhang, Liang, additional, Badillo, Maria, additional, Hartig, Kimberly H, additional, Ahmed, Makhdum, additional, Nomie, Krystle, additional, Lam, Laura T, additional, Addison, Alicia A, additional, and Romaguera, Jorge E., additional

Published
2016
Full Text
View/download PDF

47. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma

Author

Chihara, Dai, primary, Fanale, Michelle A, additional, Miranda, Roberto N., additional, Noorani, Mansoor, additional, Westin, Jason R., additional, Nastoupil, Loretta J., additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Romaguera, Jorge E., additional, Samaniego, Felipe, additional, Turturro, Francesco, additional, Lee, Hun Ju, additional, Neelapu, Sattva S., additional, Rodriguez, Alma, additional, Wang, Michael, additional, Fowler, Nathan, additional, Medeiros, L. Jeffrey, additional, Davis, Richard Eric, additional, and Oki, Yasuhiro, additional

Published
2016
Full Text
View/download PDF

48. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I Results

Author

Westin, Jason R., primary, Sathyanarayanan, Vishwanath, additional, Fayad, Luis E., additional, Nastoupil, Loretta J., additional, Turturro, Francesco, additional, Hagemeister, Fredrick B., additional, Simar, Kristin A., additional, Young, Ken H., additional, McDonnell, Timothy J., additional, Chuang, Hubert H, additional, Kamil, Fazal, additional, Feng, Lei, additional, Davis, Eric Richard, additional, Neelapu, Sattva S., additional, and Oki, Yasuhiro, additional

Published
2016
Full Text
View/download PDF

49. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Author

Fanale, Michelle A., primary, Wang, Zhiqiang, additional, Ma, Wencai, additional, Oki, Yasuhiro, additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Fowler, Nathan, additional, Romaguera, Jorge E., additional, Shah, Nina, additional, Chuang, Hubert H, additional, Lei, Feng, additional, Horowitz, Sandra B., additional, Chihara, Dai, additional, Wesson, Emily, additional, Hutto, Toni Y, additional, Ruben, Charnelle, additional, Samaniego, Felipe, additional, Muzzafar, Tariq, additional, Piekarz, Richard, additional, and Davis, R Eric, additional

Published
2015
Full Text
View/download PDF

50. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL

Author

Chihara, Dai, primary, Fanale, Michelle A., additional, Noorani, Mansoor, additional, Westin, Jason R, additional, Nastoupil, Loretta, additional, Hagemeister, Fredrick B., additional, Fayad, Luis E., additional, Romaguera, Jorge E., additional, Samaniego, Felipe, additional, Turturro, Francesco, additional, Lee, Hun Ju, additional, Neelapu, Sattva S., additional, Rodriguez, Alma, additional, Wang, Michael, additional, Fowler, Nathan, additional, Miranda, Roberto N., additional, Hosing, Chitra M., additional, Nieto, Yago, additional, Davis, Richard Eric, additional, and Oki, Yasuhiro, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results